CD19 Mouse Monoclonal Antibody [Clone ID: MRQ-36]

Specifications

Product Data
Clone Name	MRQ-36
Applications	IHC
Recommend Dilution	Immunohistochemistry on Frozen and Paraffin Sections: 1/25-1/100.  Preparation and Pretreatment: 1. Cut 3-4 μm section of formalin-fixed paraffin-embedded tissue and place on positively charged slides; dry overnight at 58°C.  2. Deparaffinize, rehydrate, and epitope retrieve; the preferred method is the use of Heat Induced Epitope Retrieval (HIER) techniques in conjunction with a pressure cooker. The preferred method allows for simultaneous deparaffinization, rehydration, and epitope retrieval. Upon completion, rinse with 5 changes of distilled or deionized water.  3. If using HRP detection system, place slides in peroxide block for 10 minutes; rinse. If using AP detection system, omit this step. Positive Control: Tonsil, Lymph Node.
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Specificity	This antibody recognizes Human CD19. Other species not tested.  Staining patter: Membranous.
Formulation	PBS, pH 7.4 State: Supernatant State: Liquid Tissue Culture Supernatant Stabilizer: 0.9% BSA Preservative: 0,09% Sodium Azide
Conjugation	Unconjugated
Storage Condition	Store undiluted at 2-8°C.
Gene Name	CD19 molecule
Database Link	Entrez Gene 930 Human UniProt ID P15391
Background	CD19 is present in both normal and malignant B cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue CD19 is observed in germinal centers (on both B cells and follicular dendritic cells), in mantle zone cells and in scattered cells in the interfollicular areas, with an overall immunoreactivity pattern similar to that of CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in pre-B cells. CD19 has also been detected by flow cytometry in plasma cells isolated from human tissues. Recently, Masir et al. have described the expression of CD19 in normal lymphoid tissue and its loss in B-cell neoplasms. CD19 positivity is seen in the lymphoid follicle in germinal centers, the mantle zone, as well as in interfollicular T-cell areas including large cells with ‘dendritic’ morphology. CD19 positivity is seen in the vast majority of B-cell neoplasms (B-lymphoblastic lymphoma, small lymphocytic lymphoma/CLL, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, T-cell-rich B-cell lymphoma, lymphoblastic lymphoma, hairy cell leukaemia) and commonly at a lower intensity than normal B-cell elements. Plasma cell neoplasms are consistently negative as are T-cell neoplasms. In the Masir study, CD19 was undetectable in 14% of diffuse large B-cell lymphomas, 30% of T-cell-rich B-cell lymphomas and 75% of post-transplant B-lymphoproliferative disease. CD19 expression is not seen in Reed-Sternberg cells of classic Hodgkin’s disease.
Synonyms	Leu-12, B-cell marker
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.